Switching To or From Leqvio (Inclisiran): What Women Need to Know

Import from '@womanrx/components'

What Is Inclisiran and How Does It Work?

Inclisiran works through a fundamentally different mechanism than any other LDL-lowering drug available today. Rather than blocking a circulating protein or inhibiting an enzyme, it silences the gene that codes for PCSK9 inside liver cells, and that difference has real consequences for how you switch into or out of it.

The RNA Interference Mechanism

Inclisiran is a small interfering RNA (siRNA) molecule. After a subcutaneous injection, it is taken up by liver hepatocytes via the GalNAc (N-acetylgalactosamine) conjugate that targets the asialoglycoprotein receptor. Inside the cell, the siRNA is loaded into the RNA-induced silencing complex (RISC), which cleaves the messenger RNA for PCSK9 before it can be translated into protein. The FDA label for inclisiran describes this as a post-transcriptional gene-silencing approach.

Because the drug acts intracellularly and the RISC complex retains silencing activity for months, a single injection suppresses PCSK9 protein for roughly six months. That is why the dosing schedule after the initial loading period is just two injections per year, administered in a clinical setting.

How This Differs from Monoclonal PCSK9 Inhibitors

Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies that bind and neutralize the PCSK9 protein after it has already been produced and secreted. They circulate in the bloodstream and require injection every two to four weeks. Inclisiran acts upstream, preventing PCSK9 from being made in the first place. The clinical result is similar, approximately 50% LDL-C reduction, but the pharmacokinetic profile is entirely different. Plasma levels of inclisiran itself fall within days of injection, while the pharmacodynamic effect persists for months because the RISC-mediated silencing continues.

This distinction matters when you are planning a switch. There is no meaningful drug-drug interaction between inclisiran and the monoclonal antibodies at the receptor level because they act at completely different points in the PCSK9 pathway.

LDL Reduction: The Numbers

The ORION-10 and ORION-11 trials published in the New England Journal of Medicine in 2020 enrolled 3,457 adults with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) already on maximally tolerated statins. Inclisiran reduced LDL-C by 49.9% in ORION-10 and 49.5% in ORION-11 compared with placebo at 510 days, with effects sustained across all measurement time points. Women represented approximately 30% of those trial populations, a figure that reflects the persistent under-representation of women in cardiovascular outcomes trials (see the evidence gap note in the section on women's-specific data below).

Switching to Inclisiran from Other LDL-Lowering Drugs

Most women who start inclisiran are not starting from scratch. They are already on a statin, ezetimibe, or a monoclonal PCSK9 inhibitor, and the transition protocol differs depending on where you are coming from.

From a Statin (Rosuvastatin, Atorvastatin, Pitavastatin)

Do not stop your statin. Inclisiran is studied and approved as an add-on therapy in patients already on maximally tolerated statin therapy. The ORION-10 trial required participants to be on stable high-intensity or maximally tolerated statin for at least 30 days before enrollment. Discontinuing your statin when you add inclisiran would give up roughly 40-55% LDL-C reduction from the statin itself for no reason.

There is no pharmacokinetic interaction between inclisiran and any statin. No dose adjustment is required for any statin when inclisiran is co-administered. You can schedule your first inclisiran dose on any day that is convenient without timing it to your statin.

From Ezetimibe

Same principle applies. Keep ezetimibe running. Ezetimibe inhibits intestinal cholesterol absorption via the NPC1L1 transporter, acting entirely outside the liver PCSK9 pathway. Inclisiran and ezetimibe are complementary. No washout, no timing requirement. In practice, a triple combination of high-intensity statin plus ezetimibe plus inclisiran can achieve LDL-C reductions exceeding 70-75% from baseline, which matters for women with homozygous or heterozygous familial hypercholesterolemia where LDL targets of <55 mg/dL are recommended by current European and American guidelines.

From Evolocumab (Repatha) or Alirocumab (Praluent)

This is the most common switching scenario in clinical practice and the one with the most nuance. No formal washout period is required, but timing matters practically.

Why Clinicians Switch Between PCSK9-Targeting Drugs

The most common reasons women switch from a monoclonal PCSK9 inhibitor to inclisiran are:

• Injection fatigue (every-two-week or monthly injections are burdensome)
• Adherence problems from the high self-injection frequency
• Insurance formulary changes or cost barriers
• Preference for in-office administration, which inclisiran requires

Occasionally, switching goes the other direction. A woman who needs flexible dosing during a planned pregnancy evaluation or who has experienced a gap in access to a clinic may transition from inclisiran back to a self-injectable monoclonal antibody.

Practical Overlap and Timing

Because evolocumab and alirocumab have half-lives of approximately 11-17 days, meaningful plasma concentrations persist for 4-8 weeks after the last dose. If you administer inclisiran immediately after stopping a monoclonal PCSK9 inhibitor, both drugs will be present simultaneously for a period. This is not dangerous. Inclisiran works intracellularly and does not compete with the antibodies for any shared receptor. There is no published safety signal for co-administration.

The pragmatic approach most lipidologists use: administer inclisiran at what would have been the next scheduled dose of the monoclonal antibody. That timing preserves LDL-C coverage without any gap and avoids any transient LDL rebound. A 2022 review in the Journal of the American College of Cardiology noted that RNA-based therapies offer continuity of effect that makes them particularly amenable to overlap transitions.

Switching Back to a Monoclonal Antibody

If you need to stop inclisiran and return to evolocumab or alirocumab, the pharmacodynamic effect of inclisiran will wane over several months as the RISC complex is gradually diluted by new hepatocyte turnover. LDL-C typically begins to rise 6-9 months after the last inclisiran injection and returns fully toward baseline by 12-18 months. You can start the monoclonal antibody at any time. There is no contraindication to beginning evolocumab or alirocumab while inclisiran's effect is still partially active, though you should monitor LDL-C at 4-6 weeks after starting to confirm response.

From Lomitapide (Juxtapid) or Mipomersen

Lomitapide and mipomersen are reserved for homozygous familial hypercholesterolemia (HoFH) and have significant hepatotoxicity concerns. If you are transitioning to inclisiran from either of these agents, work with your lipidologist to taper rather than abruptly stop. Inclisiran is not approved for HoFH as a single agent and would typically be added to an ongoing regimen rather than replacing one of these therapies entirely.

Women-Specific Physiology: What Changes Your Risk and Your Response

The standard ASCVD and FH trial populations are predominantly male, older, and post-menopausal. The way inclisiran fits into a woman's cardiovascular risk picture changes substantially depending on her life stage, hormonal status, and comorbid conditions.

Reproductive Years (Ages 20-40): PCOS, FH, and Oral Contraceptives

Women with polycystic ovary syndrome (PCOS) carry a meaningfully higher rate of dyslipidemia, with elevated LDL-C and triglycerides present in an estimated 70% of women with PCOS in some cohort studies. A 2020 meta-analysis in Human Reproduction Update confirmed that PCOS is independently associated with cardiovascular risk beyond what body weight explains.

Women with heterozygous familial hypercholesterolemia who are of reproductive age face a compounded challenge: their LDL-C is elevated from birth, oral contraceptives can raise LDL-C further depending on the progestogen used, and the most potent non-statin options (PCSK9 inhibitors including inclisiran) are either contraindicated or of unknown safety in pregnancy. Combined oral contraceptives containing androgenic progestogens such as levonorgestrel raise LDL-C by approximately 15-20 mg/dL, while desogestrel- or drospirenone-containing pills have a more neutral or slightly favorable lipid profile.

If you are in your reproductive years, using inclisiran requires reliable contraception. Pregnancy must be excluded before starting.

Perimenopause (Ages 40-55): The LDL Inflection Point

LDL-C rises by an average of 10-14 mg/dL across the menopause transition, driven by the loss of estrogen's upregulation of hepatic LDL receptors. A longitudinal analysis from the SWAN study found that LDL-C increases most sharply in the two years surrounding the final menstrual period. Women who were previously at LDL targets without medication may cross treatment thresholds during perimenopause without any change in diet or lifestyle.

This is when many women first become candidates for aggressive LDL-lowering therapy. If a woman already on a maximally tolerated statin finds herself above her LDL target in perimenopause, inclisiran is a reasonable add-on that requires only two injections per year, which matters for a life stage that already carries a high burden of clinic visits and new prescriptions.

Post-Menopause: ASCVD Risk and Undertreatment

Post-menopausal women remain significantly undertreated for hypercholesterolemia compared with age-matched men. A 2021 analysis in JAMA Cardiology found that women with established ASCVD were less likely than men to be on high-intensity statin therapy and less likely to have LDL-C <70 mg/dL. Inclisiran's twice-yearly dosing may improve adherence in this population, where polypharmacy is common and pill burden is a real barrier.

Pregnancy, Lactation, and Contraception

Inclisiran is contraindicated in pregnancy. This is not a precautionary recommendation based on theoretical risk. The drug has not been studied in pregnant women, and its mechanism of gene silencing at the RNA level raises legitimate concerns about effects on fetal lipid metabolism, which is essential for normal fetal development. Cholesterol is required for fetal neurogenesis, myelin formation, and steroidogenesis. Any agent that substantially suppresses hepatic PCSK9 and upregulates LDL receptor activity in the maternal liver could theoretically alter fetal lipid availability, though the degree of fetal exposure from maternal siRNA administration is unknown.

The FDA prescribing information for inclisiran states that animal reproductive studies have not been conducted with inclisiran, and there are no data in pregnant women. The label advises discontinuing inclisiran when pregnancy is recognized.

What This Means Practically

• Exclude pregnancy before starting inclisiran.
• Use reliable contraception throughout treatment if you are of reproductive potential.
• If you become pregnant while on inclisiran, stop the drug immediately and notify your provider.
• Because inclisiran's pharmacodynamic effect persists for months after the last dose, discuss with your clinician how long after stopping inclisiran you should wait before attempting conception. No specific interval is defined in the label, but a conservative approach of allowing LDL levels to return toward baseline before conception (approximately 6-12 months) is reasonable and consistent with how teratogenic drug effects are managed in other contexts.
• Statins are also contraindicated in pregnancy. If you stop inclisiran for conception, a statin washout is also required.

Lactation

Transfer of inclisiran into human breast milk has not been studied. GalNAc-conjugated siRNA molecules are large and complex enough that oral bioavailability in a nursing infant would likely be negligible, but this has not been formally tested. The manufacturer's guidance advises against using inclisiran while breastfeeding due to the absence of data. Given that hypercholesterolemia is not acutely life-threatening and the drug's effects persist for months, the practical recommendation is to defer inclisiran until after weaning.

Postpartum and the Lipid Rebound

Cholesterol rises physiologically during pregnancy and typically normalizes by 6-8 weeks postpartum. Women with FH or pre-existing dyslipidemia may not return to their pre-pregnancy baseline and may exit the postpartum period with LDL-C higher than before pregnancy. This is a reasonable time to revisit whether add-on therapy including inclisiran is appropriate, once breastfeeding is complete.

Evidence Gaps in Women: What We Know and What We Are Extrapolating

The ORION program is large and rigorous, but women's representation was limited. In ORION-10 and ORION-11, women comprised approximately 30-32% of the study population. That means the 50% LDL-C reduction headline number is predominantly derived from male participants. A secondary analysis from the ORION trials did not show a statistically significant sex-based difference in LDL-C response, which is reassuring, but the confidence intervals in women are wider than in men simply due to sample size.

No dedicated pharmacokinetic study of inclisiran has been conducted in women across the menstrual cycle, in perimenopausal women with fluctuating estrogen, or in women on hormonal contraception. The GalNAc receptor expression in hepatocytes is not known to be sex-hormone dependent, which makes a major sex-difference in uptake unlikely, but it has not been directly tested.

The honest clinical picture: the LDL-lowering efficacy data are likely generalizable to women, but we are extrapolating. The pregnancy and lactation data are essentially absent. Women with the most complex situations, FH in pregnancy, PCOS with metabolic syndrome, post-menopausal women on hormone therapy, have no dedicated trial data. When you ask your clinician whether inclisiran is right for you in one of these situations, the honest answer will involve some degree of extrapolation from the general population data.

Who Is a Good Candidate for Inclisiran and Who Should Wait

Good Candidates

• Post-menopausal women with established ASCVD or HeFH already on maximally tolerated statin therapy who remain above their LDL target
• Women with statin-associated muscle symptoms who are on a low-intensity statin or no statin and need substantial additional LDL-C lowering
• Women with injection fatigue from biweekly evolocumab or monthly alirocumab who prefer in-office biannual dosing
• Women with adherence challenges related to daily oral medications (inclisiran removes one more daily pill)

Women Who Should Pause or Choose a Different Option

• Any woman who is pregnant or planning conception in the near term
• Women who are breastfeeding
• Women whose insurance does not cover inclisiran and who face a substantial out-of-pocket cost (evolocumab and alirocumab have patient assistance programs with different coverage structures)
• Women with active liver disease (GalNAc delivery depends on healthy hepatocyte function and asialoglycoprotein receptor expression)

Practical Switching Checklist for the Clinical Visit

Before your provider schedules your first inclisiran injection, you and your clinician should confirm the following:

1. Pregnancy status documented (negative urine or serum hCG if any possibility of pregnancy).
2. Contraception plan confirmed if you are of reproductive potential.
3. Breastfeeding status reviewed.
4. Current LDL-lowering regimen documented: which statin, which dose, whether ezetimibe is on board.
5. If switching from evolocumab or alirocumab: date of last injection recorded and inclisiran timing coordinated to the next scheduled antibody dose window.
6. Baseline LDL-C drawn within the prior 3 months.
7. Liver function tests reviewed (no specific monitoring requirement in the label, but baseline is reasonable given hepatic delivery mechanism).
8. Follow-up LDL-C planned at 3 months after the first injection to confirm response before the second loading dose.

Monitoring After Switching

Inclisiran does not require lipid monitoring on a rigid schedule the way newly initiated statins do, but checking LDL-C at approximately 3 months after the first injection establishes your individual response. A second check at 6 months (just before or just after your second injection) gives a picture of the nadir and helps your clinician decide whether any additional therapy adjustment is needed.

Women switching from a monoclonal PCSK9 inhibitor should expect their LDL-C trajectory to remain stable through the transition. A transient LDL-C rise of 5-10% is sometimes seen in the window between the last monoclonal antibody dose and the onset of full inclisiran effect (roughly 30 days from the first inclisiran injection), but this is clinically minor in most women and does not require bridging therapy.

If you experience a 30% or greater LDL-C rebound at your 3-month check after switching from a monoclonal antibody, revisit whether the injection was administered correctly and whether there are adherence or injection technique issues, since inclisiran is administered by a clinician rather than self-injected and technique errors are uncommon but not impossible.